Clinical Trial News Archive - August 2025
August 1, 2025
August 4, 2025
August 6, 2025
August 7, 2025
- Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of Up To an Average of 27.3 lbs in First of Two Pivotal Phase 3 Trials in Adults with Obesity
- Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia
- Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
August 11, 2025
- Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
- Novartis Announces Both Ianalumab Phase III Clinical Trials Met Primary Endpoint in Patients with Sjögren’s Disease
August 12, 2025
August 13, 2025
- Two-Dose Dalbavancin Therapy for Staphylococcus Aureus Bloodstream Infections on Par with Standard Treatment
- Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 14, 2025
August 15, 2025
August 18, 2025
- Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
- Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Novo Nordisk Lowers Cost of Ozempic to $499 per Month for Self-Paying Patients
- FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
August 19, 2025
- Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
August 25, 2025
- Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine Ixchiq In the U.S.
- Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 26, 2025
- Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity
- Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis
August 27, 2025
August 30, 2025
- Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
- Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial
August 31, 2025
Clinical trial results archive
- 2025
- January, February, March, April, May, June, July, August, September
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.